Enrique Bellolio
University of La Frontera
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Enrique Bellolio.
Journal of Dermatology | 2014
Cristian Pinto; Mauricio Lechuga; Enrique Bellolio; Sergio González; Fabiola Schafer
1 Borhan R, Vignn-Pennamen MD, Morel P. Lupus miliaris disseminates faciei: 6 cases. Ann Dermatol Venereol, 2005; 132: 526–530. 2 AI-Mutairi N. Nosology and therapeutic options for lupus miliaris disseminates faciei. J Dermatol, 2011; 38: 864–873. 3 Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet, 1976; 1: 1211–1212. 4 Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol, 1980; 102: 443–444.
Molecular Cancer Research | 2016
Carmen Ili; Tamara Viscarra; J. C. Araya; Jaime Lopez; Bárbara Mora; Javier Retamal; Susana Aedo; Enrique Bellolio; Juan Carlos Roa; Priscilla Brebi
Introduction: Cervical Cancer (CC) is an important heath problem in developing countries. The silencing of tumor suppressor genes (TSG) could be implied in cervical carcinogenesis. Methylation microarray showed an aberrant hypermethylation of FKBP6, a potential TSG gen in CC. The aim of this study was to characterizer FKBP6 role in cervical carcinogenesis. Materials and methods: ECT1 E6/E7 (immortalized normal squamous epithelia cell line) and three CC cell lines: SiHa, C-4I and C-33A were cultivated for experiments. FKBP6 expression was determined by qRT-PCR and western blot. Treatment with 10 μM 5-aza-2′deoxycytidine (5-aza) was performed to evaluate a possible epigenetic regulation. Transfection with pCMV6-FKBP6-GFP (FKBP6) and pCMV6-GFP (Empty) was carried out in SiHa cell line through lipofection followed by G418 selection to obtain stable transfection. Viability and clonogenic assay was performed to evaluate transfected cell behaviour. In other hand, 497 biopsy samples of the cervix were analyzed by FKBP6 immunohistochemistry (48 normal; 192 low-squamous intraepithelial lesions; 200 high- squamous intraepithelial lesions and 57 squamous cervical cancers). Results: FKBP6 mRNA and protein expression was significantly downregulated in all cervical cancer cell lines respect to ECT1 E6/E7. In western blot, also could be observed a variant of FKBP6 mainly in C-4I cell line. After treatment with 5-aza, mRNA (p Conclusions: There is a FKBP6 dysregulation in CC cell lines, and the inactivation mechanism seems to be methylation. Restored expression of FKBP6 in SiHa cell line modifies the tumor phenotype, decreasing colony formation, but increasing cell viability. These results suggest that FKBP6 could be implied in cervical progression, but more studies are necessary to evaluate FKBP6 functions in cervical cancer. Acknowledgments: FONDECYT N°3130630, Project Corfo N° 09CN14-5960, Project Corfo N°12IDL2-18157. Project FONDECYT N° 11150802, Project FONDECYT N°1115062 Citation Format: Carmen Gloria Ili, Tamara Viscarra, Juan Carlos Araya, Jaime Lopez, Barbara Mora, Javier Retamal, Susana Aedo, Enrique Bellolio, Juan Carlos Roa, Priscilla Brebi. FKBP6 gene is involved in progression of cervical cancer. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; Feb 28-Mar 2, 2016; Orlando, FL. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(11_Suppl):Abstract nr B28.
Metastases and EMT | 2018
Carmen Ili; Javier Retamal; Jaime Lopez; Ismael Riquelme; Enrique Bellolio; Tamara Viscarra; L Zanella; M Abanto; Kurt Buchegger; Priscilla Brebi
Introduction Colorectal cancer (CRC) is an important public health problem worldwide. In Chile, CRC is the fourth most frequent cancer and its incidence is rising. Sporadic CRC results from the accumulation of both acquired genetic and epigenetic changes that transform normal glandular epithelium into invasive adenocarcinoma. DNA methylation has an important role in colon carcinogenesis and also has been found involved in metastasis pathways of CRC. However, there are no studies that analysed whole genome in the search of specific methylated genes in metastasis of CRC, despite the next-generation sequencing platforms and methylation arrays available. Therefore, in this project it is proposed to find novel methylation markers of metastasis by comparing primary tumours and their corresponding lymph node metastasis, using a next-generation sequencing platform. The aim of this study was to identify differentially methylated genes associated with metastasis tumour behaviour in colorectal cancer. Material and methods Five paired FFPE samples of CRC primary tumour and its corresponding lymph node metastasis were analysed with genome-wide Methyl-Seq bisulfite sequencing. Five differently hypomethylated genes were selected using bioinformatics tools. Bioinformatic analysis was realised comparing colorectal primary tumour vs lymph node metastasis using methylKit tool. Results and discussions A total of 196 genes were detected as differentially methylated in their promoter region, 94 of which were hypomethylated on lymph node metastasis group. CS, RNF130, HERC6, ZNF717 and RNF216-IT1 genes presented differences over 50% in their methylation status, compared with CRC primary tumours group. According to their ontology, these genes are involved on regulation of tricarboxylic acid cycle, transcription, carbohydrate metabolic process and protein polyubiquitination. Conclusion CS, RNF130, HERC6, ZNF717 and RNF216-IT1 genes were found hypomethylated in colorectal metastasis compared to primary tumour. These genes could be implied in metastasis behaviour in colorectal cancer, but further studies are necessary to evaluate their functions.
Molecular Cancer Research | 2016
Carmen Ili; Tamara Viscarra; J. C. Araya; Jaime Lopez; Bárbara Mora; Javier Retamal; Enrique Bellolio; Susana Aedo; Juan Carlos Roa; Priscilla Brebi
Background: In Cervical Cancer (CC) the role of HPV is fundamental; however, not all HPV infected women will develop this disease. Therefore, other mechanisms, such as silencing of tumor suppressor genes (TSG), could be implied in cervical carcinogenesis. In a previous study, we constructed methylation microarrays, where we found promoter aberrant hypermethylation of ZNF516 gen in CC, postulating it as TSG candidate. The aim of this study was to characterizer ZNF516 role in cervical carcinogenesis and cell cycle. Materials and methods: ECT1 E6/E7 (immortalized normal squamous epithelia cell line) and three CC cell lines: SiHa, C-4I and C-33A were cultivated for experiments. ZNF516 expression was determined by qRT-PCR and western blot. Treatment with 10 μM 5-aza-2′deoxycytidine (5- aza) was performed to evaluate a possible epigenetic regulation. Transfection with pCMV6-ZNF516-GFP (ZNF516) and pCMV6-GFP (Empty) was carried out in C-33A cell line through lipofection followed by G418 selection to obtain stable transfection. Viability and clonogenic assay was performed to evaluate transfected cell behaviour. Also, immnunohistochemical analysis was performed in 509 cervical biopsy tissues (55 normal; 188 low-squamous intraepithelial lesions; 205 high- squamous intraepithelial lesions and 57 squamous cervical cancers). Results: ZNF516 mRNA expression was significantly downregulated in SiHa (p Conclusions: There is a clear ZNF516 dysregulation in CC cell lines, and the inactivation mechanism seem to be methylation. Restored expression of ZNF516 in C-33A cell line modifies the tumor phenotype, decreasing cellular viability and colony formation. These results suggest that ZNF516 could be a TSG, and its inactivation promotes CC developing. Citation Format: Carmen Gloria Ili, Tamara Viscarra, Juan Carlos Araya, Jaime Lopez, Barbara Mora, Javier Retamal, Enrique Bellolio, Susana Aedo, Juan Carlos Roa, Priscilla Brebi. ZNF516 a potential tumor suppressor gene candidate is implied in tumor progression in cervical cancer. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; Feb 28-Mar 2, 2016; Orlando, FL. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(11_Suppl):Abstract nr B29.
Revista Medica De Chile | 2015
Enrique Bellolio; Viviana Pineda; Maria Eugenia Burgos; María José Iriarte; Renato Becker; J. C. Araya; M. Villaseca; Noldy Mardones
BACKGROUND To validate the BIRADS in mammography, the calculation of its predictive value in each center is required, as recommended by the American College of Radiology. AIM To determine the predictive value of the BIRADS system in our center. MATERIAL AND METHODS All ultrasound guided needle percutaneous biopsies, performed at our center between 2006 and 2010 were reviewed. Predictive value, sensitivity, specificity and diagnostic accuracy of BIRADS were calculated, with a confidence interval of 95%. RESULTS Of 1,313 biopsies available, 1,058 met the inclusion criteria. Fifty eight percent of biopsies were performed to women with mammographies classified as BIRADS 4 or 5. The presence of cancer in mammographies classified as BIRADS 0 was 4%. The prevalence of cancer for mammographies BIRADS 1, 2, 3, 4 and 5 were 0, 3, 2.7, 17.7 and 72.4% respectively. The positive and negative predictive values of BIRADS classification were 55 and 92 % respectively. CONCLUSIONS In our institution BIRADS classification 4 and 5 has a high positive predictive value for detecting cancer as in developed countries.Background: To validate the BIRADS in mammography, the calculation of its predictive value in each center is required, as recommended by the American College of Radiology. Aim: To determine the predictive value of the BIRADS system in our center. Material and methods: All ultrasound guided needle percutaneous biopsies, performed at our center between 2006 and 2010 were reviewed. Predictive value, sensitivity, specificity and diagnostic accuracy of BIRADS were calculated, with a confidence interval of 95%. Results: Of 1313 biopsies available, 1058 met the inclusion criteria. Fifty eight percent of biopsies were performed to women with mammographies classified as BIRADS 4 or 5. The presence of cancer in mammographies classified as BIRADS 0 was 4%. The prevalence of cancer for mammographies BIRADS 1, 2, 3, 4 and 5 were 0, 3, 2.7, 17.7 and 72.4% respectively. The positive and negative predictive values of BIRADS classification were 55 and 92 % respectively Conclusions: In our institution BIRADS classification 4 and 5 has a high positive predictive value for detecting cancer as in developed countries.
Revista Medica De Chile | 2012
Yesenia Valenzuela; Constanza Ramírez; Enrique Bellolio
Background: We report a 35-year-old female patient with a one year history of a pustular and painful erythematous dermatitis, located in great folds, pubis and abdomen. She was evaluated in primary health care, receiving antifungal treatment, antimicrobials, topical and systemic non-steroidal anti-inflammatory drugs, with no response. A skin biopsy was compatible with subcorneal pustular dermatosis. She was initially treated with prednisone (0.8 mg/kg), observing a partial response. Therefore clotrimoxazole was initiated, obtaining an excellent response after 30 days of treatment
Virchows Archiv | 2014
Oscar Tapia; Ismael Riquelme; Pamela Leal; Alejandra Sandoval; Susana Aedo; Helga Weber; Pablo Letelier; Enrique Bellolio; M. Villaseca; Patricia García; Juan Carlos Roa
Human Pathology | 2017
Deniz Tuncel; Juan Roa; J. C. Araya; Enrique Bellolio; M. Villaseca; Oscar Tapia; Kee-Taek Jang; Brian Quigley; Burcu Saka; Olca Basturk; Juan M. Sarmiento; Héctor Losada; Samip Patel; Michelle D. Reid; Bahar Memis; Volkan Adsay
Journal of Postgraduate Medicine | 2013
Enrique Bellolio; Fabiola Schafer; R Becker; M. Villaseca
Human Pathology | 2018
Jill Koshiol; Enrique Bellolio; Carolina Vivallo; Paz Cook; Juan Carlos Roa; Emma E. McGee; Héctor Losada; Alison L. Van Dyke; Vanessa Van De Wyngard; Rodrigo Prado; M. Villaseca; Pia Riquelme; Johanna Acevedo; Vanessa Olivo; Karen Pettit; Allan Hildesheim; Karie Medina; Bahar Memis; Volkan Adsay; Catterina Ferreccio; Juan Carlos Araya